215 related articles for article (PubMed ID: 18446520)
1. Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.
Harper TW; Brassil PJ
AAPS J; 2008; 10(1):200-7. PubMed ID: 18446520
[TBL] [Abstract][Full Text] [Related]
2. Reaction phenotyping to assess victim drug-drug interaction risks.
Di L
Expert Opin Drug Discov; 2017 Nov; 12(11):1105-1115. PubMed ID: 28820269
[TBL] [Abstract][Full Text] [Related]
3. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 reaction-phenotyping: an industrial perspective.
Zhang H; Davis CD; Sinz MW; Rodrigues AD
Expert Opin Drug Metab Toxicol; 2007 Oct; 3(5):667-87. PubMed ID: 17916054
[TBL] [Abstract][Full Text] [Related]
5. Reaction phenotyping in drug discovery: moving forward with confidence?
Williams JA; Hurst SI; Bauman J; Jones BC; Hyland R; Gibbs JP; Obach RS; Ball SE
Curr Drug Metab; 2003 Dec; 4(6):527-34. PubMed ID: 14683480
[TBL] [Abstract][Full Text] [Related]
6. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes.
Zientek MA; Youdim K
Drug Metab Dispos; 2015 Jan; 43(1):163-81. PubMed ID: 25297949
[TBL] [Abstract][Full Text] [Related]
7. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions.
Crespi CL; Penman BW
Adv Pharmacol; 1997; 43():171-88. PubMed ID: 9342176
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Drug Metabolism Using Liver Microsomes.
Knights KM; Stresser DM; Miners JO; Crespi CL
Curr Protoc Pharmacol; 2016 Sep; 74():7.8.1-7.8.24. PubMed ID: 27636111
[TBL] [Abstract][Full Text] [Related]
9. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
Tanaka E; Kurata N; Yasuhara H
J Clin Pharm Ther; 2003 Jun; 28(3):157-65. PubMed ID: 12795773
[TBL] [Abstract][Full Text] [Related]
10. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.
Venkatakrishnan K; Von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 2001 Nov; 41(11):1149-79. PubMed ID: 11697750
[TBL] [Abstract][Full Text] [Related]
11. In vitro metabolism, reaction phenotyping, enzyme kinetics, CYP inhibition and induction potential of ataluren.
Kong R; Ma J; Hwang S; Moon YC; Welch EM; Weetall M; Colacino JM; Almstead N; Babiak J; Goodwin E
Pharmacol Res Perspect; 2020 Apr; 8(2):e00576. PubMed ID: 32196986
[TBL] [Abstract][Full Text] [Related]
12. Drug metabolizing enzymes related to laboratory medicine: cytochromes P-450 and UDP-glucuronosyltransferases.
Batt AM; Magdalou J; Vincent-Viry M; Ouzzine M; Fournel-Gigleux S; Galteau MM; Siest G
Clin Chim Acta; 1994 May; 226(2):171-90. PubMed ID: 7923812
[TBL] [Abstract][Full Text] [Related]
13. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.
Chen Y; Liu L; Nguyen K; Fretland AJ
Drug Metab Dispos; 2011 Mar; 39(3):373-82. PubMed ID: 21148079
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.
den Braver-Sewradj SP; den Braver MW; Baze A; Decorde J; Fonsi M; Bachellier P; Vermeulen NPE; Commandeur JNM; Richert L; Vos JC
Eur J Pharm Sci; 2017 Nov; 109():96-110. PubMed ID: 28778465
[TBL] [Abstract][Full Text] [Related]
16. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.
Streetman DS; Bertino JS; Nafziger AN
Pharmacogenetics; 2000 Apr; 10(3):187-216. PubMed ID: 10803676
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach.
de Andrés F; LLerena A
Curr Pharm Biotechnol; 2016; 17(13):1159-1180. PubMed ID: 27677273
[TBL] [Abstract][Full Text] [Related]
18. In vitro assessment of the allelic variants of cytochrome P450.
Hiratsuka M
Drug Metab Pharmacokinet; 2012; 27(1):68-84. PubMed ID: 22041138
[TBL] [Abstract][Full Text] [Related]
19. [Investigation of metabolic kinetics and reaction phenotyping of ligustrazin by using liver microsomes and recombinant human enzymes].
Tan Y; Zhuang XM; Shen GL; Li H; Gao Y
Yao Xue Xue Bao; 2014 Mar; 49(3):374-9. PubMed ID: 24961110
[TBL] [Abstract][Full Text] [Related]
20. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.
Rodrigues AD
Biochem Pharmacol; 1999 Mar; 57(5):465-80. PubMed ID: 9952310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
